Reorganisation & Directorate

Fulcrum Pharma PLC
27 September 2004


For immediate release                                          27 September 2004


                               Fulcrum Pharma Plc


                   European reorganisation and Board change



Fulcrum Pharma plc (AIM: FUL), the independent drug development company that
offers virtual drug development and strategic outsourcing services to the
pharmaceutical and biotechnology industries, today announces that it has
reorganised its European business to meet the needs of the market.



This reorganisation is in line with the strategy summarised in the trading
update issued on 6 August 2004 in which Fulcrum said it would leverage its
position by concentrating investment in the US, where growth is fastest, and
continue to drive cross sales out of Japan to the US and Europe.



The European reorganisation focuses on tailoring Sales and Marketing and
Business Development efforts to each market to enhance the Company's ability to
win new business.



European Sales and Business Development will be merged with Operations and will
be led by Dr Sarah Arbe-Barnes.  Sarah has worked as Director of Operations at
Fulcrum since March 2000.  Sarah will be joined by a dedicated Business
Development Director, Ashley Nagle, who joins from CSS, a services organisation
in Ireland that specialises in manufacturing and was formerly a subsidiary of
Galen Holdings plc, where he was Business Development Manager for Europe and
Japan.



In the US and Japan Dr Bruce McCreedy and Dr Alastair Devlin will continue to
head Fulcrum's operations respectively.



As a consequence of this reorganisation there is no longer a need for a global
Commercial Director and regretfully Neil Oughton, who has filled this role as
well as the role of Director and Company Secretary since Fulcrum floated on AIM
in 2000, will be leaving the Company at the end of September and has resigned
from the Board.  Neil will continue to work for the Company as a consultant over
the next six months.  Lesley Wotherspoon, Financial Controller, will take over
as Company Secretary with immediate effect.





Commenting on today's announcement, Jon Court, Chief Executive of Fulcrum, said:



'The Board wishes to thank Neil for his hard work and dedication to the Company
since he joined Fulcrum in 2000.  As a fellow founder of Fulcrum, I wish him
good luck in the future.   As the Company moves forward I am confident that
Sarah will use her business development and sales experience to good effect in
her new role and help to make the team highly effective.'



                                    - Ends -



For further information, please contact :



Fulcrum Pharma plc

Jon Court, Chief Executive                                [phone]


Buchanan Communications

Mary-Jane Johnson                                         [phone]




Notes to Editors:



Fulcrum Pharma plc is an independent, strategic, drug development services
company that aims to be the pharmaceutical industry's first choice for optimal
management of drug development.



Fulcrum offers a unique strategic drug development service to the pharmaceutical
and biotechnology industries. The company provides customized development
programmes that lead to early Proof of Concept, efficient registration and ideal
positioning for rapid availability to patients. Fulcrum's service is
professional and cost-effective.



Fulcrum's experienced senior managers personally oversee drug development
projects via an advanced management process, combining exceptional project
leadership and problem solving skills with an external team of specifically
selected suppliers and independent experts to meet the needs of our clients.



Fulcrum Pharma is listed on the Alternative Investment Market of the London
Stock Exchange. For more information please visit www.fulcrumpharma.com




                      This information is provided by RNS
            The company news service from the London Stock Exchange